In the clinically evaluable population ( n = 498 ) 217 ( 84 % ) of 258 patients in the ceftaroline fosamil group and 178 ( 74 % ) of 240 patients in the ceftriaxone group were clinically cured at the test-of-cure visit ( difference 99 % , 95 % CI 28-171 ) .